About InVivoSIM anti-human CD20 (Ublituximab Biosimilar) This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ublituximab, making it ideal for research use. Ublituximab is a chimeric IgG1 monoclonal antibody that targets CD20, a transmembrane phosphoprotein expressed on pre‑B and mature B lymphocytes but not on plasma cells. CD20 is involved in B cell activation, proliferation, and calcium signaling. Ublituximab binds a unique epitope on CD20 and mediates potent B cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC). The original therapeutic antibody is glycoengineered for enhanced FcγRIIIa binding and effector function, though this research-grade biosimilar is not afucosylated. This Ublituximab biosimilar is ideal for exploring CD20 biology, B cell–mediated diseases, and mechanisms of B cell depletion in cancer and autoimmunity. InVivoSIM anti-human CD20 (Ublituximab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman CD20 Reported ApplicationsIn vivo functional assays in vitro functional assays Flow cytometry ELISA FormulationpH 7.0 Contains no stabilizers or preservatives Endotoxin≤0.5EU/mg (≤0.0005EU/μg)Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity≥95%Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
